Acute lymphoblastic leukemia (ALLs) expressing MLL-AF4, the fusion product of t(4;11)(q21;q23), show marked leucocytosis and extramedullary disease in multiple organs, respond poorly to chemotherapy and have poor prognosis. In vitro, leukemic cells with the t(4;11) show resistance to serum deprivationinduced or interferon c-regulated CD95-mediated apoptosis. In addition, t(4;11) cells have prolonged doubling time and lower percentage of cells in cycle compared to non-t(4;11) B lineage cell lines. In this study, we examine the time-and leveldependent effects of MLL-AF4 conditional expression on cell cycle and differentiation of myelomonocytic leukemia cell line U937. By varying the concentration of tetracycline in growth media, we found that increasing levels of MLL-AF4 expression result in a progressive decrease in growth rate and fraction of S phase cells, paralleled by an increase in percentage of cells expressing CD11b. Our results demonstrate a dosage-dependent effect of MLL-AF4 fusion oncoprotein on cell cycle progression, with increasing expression levels resulting in the accumulation in G1, prolonged doubling time, both findings that might be responsible for the increased resistance to etoposide-mediated cytotoxicity. We propose the cell cycle control exerted by MLL-AF4 may be responsible of resistance to cell-death promoting stimuli in leukemia carrying the t(4;11) translocation.
Introduction
The MLL gene (also known as ALL-1, HRX, and Htrx1), the mammalian homolog of Drosophila gene trithorax, is target of more than 30 reciprocal translocations. 1, 2 Breakpoints within the 100 kilobase (kb) MLL gene are localized in an 8.5 kb breakpoint cluster region positioned between exons 8 and 14, with reciprocal translocations resulting in the replacement of MLL 3 0 coding sequences by the translocation partner. 3 The vast number of MLL partner genes that have been cloned to date share little sequence homology and associate preferentially to different subtypes of acute myeloblastic leukemia (AML), ALL (acute lymphoblastic leukemia), or myelodysplastic syndromes (MDS). 4 The MLL gene encodes for a predicted 431 kDa protein that is proteolytically processed into amino terminal p300 and carboxyl terminal p180 fragments, which form an MLL stable complex in vivo. [5] [6] [7] The resulting chimeric proteins include the amino terminal half of MLL fused in frame to different partner gene products where this heterogeneity of partner sequences, together with the impaired ability to complex with the carboxyl terminal p180 fragment highly homologous to trithorax, argue for a leukemogenic role played by the amino terminal half of MLL. Indeed, the truncated MLL protein is sufficient for tumorigenesis when artificially fused in-frame to bacterial bgalactosidase in mice. The amino terminus of MLL, containing three AT hook DNA binding motifs, confers subnuclear localization of MLL fusion proteins identical with that of native protein, suggesting that deregulation of common target loci may promote tumorigenesis. [8] [9] [10] [11] [12] [13] Likewise, the dominant gain of transcriptional effector or homo-dimerization properties contributed by few partner genes to the MLL-mediated leukemogenesis has been clearly demonstrated in an retroviral transduction/transplantation assay (reviewed by Ayton and Cleary 14 ) ). Thus, the contribution of both the amino terminal half of MLL and the partner protein should be carefully analyzed in an effort to understand the leukemogenic role of an MLL fusion protein.
The AF4 partner gene of the most common 11q23 rearrangement, the t(4;11)(q21;q23), is predominantly found fused in frame to MLL in pro-B ALLs (CD10 À /Cd19 þ ) in infants and less frequently in children and adults. [15] [16] [17] [18] [19] Several studies indicate the t(4;11) in infant ALL as the only MLL-related translocation associated with a dismal outcome (reviewed by Biondi et al 20 )
. By using a tetracycline repressor-based conditional expression system, we previously found that MLL-AF9, the product of the t(9;11)(p22;q23), is a potent inducer of growth arrest, macrophage differentiation, and ultimately cell death when overexpressed in the myelomonocytic leukemia cell line U937. In addition, amino terminal MLL fragments spanning two or three AT hook DNA-binding motifs (MLL2AT and MLL3AT) were found sufficient for both cell cycle arrest, upregulation of p21 Cip1 and p27
Kip1
, and partial differentiation toward macrophages. 21 In the present study, we have examined the time-and leveldependent effects of MLL-AF4 conditional expression on cell cycle, differentiation, and drug-sensitivity of U937T cells by taking advantage of the tetracycline-regulatable system [23] [24] [25] as a reliable methodology for controlling the amount of ectopic expression.
Materials and methods

Vectors and cell lines conditionally expressing MLL-AF4
The pUHD-10S expression vector under control of a tetracycline-responsive promoter, the pUHD/MLL-AF4 construct encoding a FLAG epitope-tagged MLL-AF4, and the pGEM-HYG plasmid encoding resistance to hygromycin (HygB) were previously described. 13, 21, 22 The human myelomonocytic leukemia cell line U937T was obtained by stable transfection of U937 with the pUHD/tTApuro vector, thereby making tTA expression tetracycline repressible and autoregulatory. [23] [24] [25] U937T cells were routinely cultured in RPMI 1640 medium supplemented with 10% FCS (RPMI-F), 0.5 mg/ml puromycin and 1 mg/ml tetracycline. U937T clones conditionally expressing MLL-AF9 or MLL3AT proteins were generated as previously described. 21 Electroporation was used to stably cotransfect exponentially growing U937T cells with a 10-fold molar excess of pUHD/MLL-AF4 and the pGEM-HYG. HygB-resistant mixed cell populations expressing MLL-AF4 were subcloned by limiting dilution in 96-well cell culture plates and expanded in RPMI-F, 0.5 mg/ml puromycin, 0.4 mg/ml HygB, and 1 mg/ml tetracycline. Clones with tetracycline-regulated MLL-AF4 expression were identified as described previously, 21 by indirect immunofluorescence analysis employing a a-FLAG mAb (Sigma) or the a-AF4 C15 pAb. 26 U937T clones expressing MLL-AF4, MLL-AF9, or MLL3AT were routinely maintained in RPMI-F, 1 mg/ml tetracycline, 0.5 mg/ml puromycin, and 0.4 mg/ml HygB.
Western blot analysis
Aliquots of 5 Â 10 6 cells were lysated in NP-40 buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40) containing a mixture of protease inhibitors (Complete tablets, Roche), and sonicated at maximum intensity for 10 s. The cell lysate was incubated 30 min on ice and the protein concentration measured by Bradford assay (BioRad). Of each sample, 50 mg were boiled in 2 Â Laemmli buffer, run on 5 or 15% SDS-PAGE and subsequently blotted on nitrocellulose membranes. Membranes were blocked for 1 h with 5% skim milk powder in PBS at room temperature, incubated for 16 h with affinity purified rabbit a-MLL M382 pAb, 13 a-Actin pAb, a-BclX L pAb (Santa Cruz Biotechnology) and a-Bcl2 mAb (Oncogene) in 3% skim milk powder in PBS at 41C, and washed three times in PBS 0.05% Tween 20 (TPBS), 10 min each. The filters were then incubated for 1 h with HRP (horseradish peroxidase)-conjugated donkey a-rabbit or sheep a-mouse IgG (Amersham Biosciences) and washed four times in TPBS at room temperature. The protein was detected by chemiluminescence following Super signal ULTRA protocol (Pierce).
Real-time quantitative PCR (RQ-PCR)
Total RNA and cDNA from U937T clones grown 72 h at various tetracycline concentrations were prepared as previously described. 27 For RQ-PCR analysis the TaqMan PCR master mix 2 Â reagent was used (Applied Biosystems). Reaction mixtures of 25 ml contained 2.5 ml TaqMan buffer A with the ROX dye as the passive reference, 5.5 mM MgCl 2 , 0.2 mM dNTP, 0.3 mM primers, 0.2 mM probe, 1.25 U AmpliTaq Gold, and 100 ng of RNA equivalent-cDNA. The amplification protocol consisted of 10 min at 951C (denaturation of target DNA, and activation of AmpliTaq Gold), followed by target amplification via 50 cycles of 15 s at 951C and 1 min at 601C.
Real-time analysis was performed on the ABI PRISM 7900 Sequence Detection System containing a 96-well thermal cycler (Applied Biosystems). All samples were tested in triplicate. To correct for the quantity and quality (amplificability) of sample's cDNA, the Abl housekeeping gene was amplified. The primers and probes for MLL-AF4 fusion gene and Abl gene transcripts were selected according to the previously described method. 28 Primers and probe for MLL-AF9 fusion gene were defined using the Primer Express Software (Applied Biosystems); sequences of the primers and probes are:
0 . The quantification of target RNA for fusion genes and Abl was calculated on standard curves performed by amplifying a 10-fold serial dilution of target cDNA in water. PCR efficiency was very similar in all RT-Q-PCR reactions (slope MLL-AF4: À3.25, slope MLL-AF9: À3.73). The MLL-AF4/Abl and MLL-AF9/Abl ratio was calculated and the normalized values of the fusion gene transcripts were reported as the ratio value Â 10 000.
Cell proliferation and cytotoxicity
Exponentially growing U937T clones were repeatedly washed with 2% FCS in PBS, to remove tetracycline, and diluted at cell density of 5 Â 10 4 cell/ml in RPMI-F plus 0.5, 1, 2, 3, 1000 ng/ml or without tetracycline. For the trypan blue dye-exclusion assay, the cells were plated in triplicate in six-well cell culture plates and cultured for 5 days. Proliferation rate was assessed every 24 h by direct counting of stained (dead) and unstained (live) cells using a hemocytometer. Cytotoxicity studies were performed using the MTT proliferation assay (Promega). The cells were cultured 48 h with or without tetracycline to induce the expression of MLL-AF4, treated with various concentrations of etoposide (VP-16), and plated in triplicate at 5 Â 10 4 cell/ml in 96-well cell culture plates. After 48 h of treatment, 15 ml of MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well and incubated for 4 h at 371C. The reaction was stopped by adding 100 ml of the Solubilization/ Stop Solution (Promega) and the quantity of reduced product was measured at 570 nm using an ELISA (enzyme-liked immunosorbent assay) plate reader. The mean of optical density at 570 nm (OD 570 ) is linearly related to the number of viable cells. The percentage of cell survival with or without graded MLL-AF4 expression was calculated as:
Mean OD 570 in drug treated cells Mean OD 570 in control cells Â100
Cell cycle analysis and immunophenotyping
U937T clones were washed in 2% FCS in PBS, diluted at a cell density of 5 Â 10 4 cells/ml in RPMI-F with the indicated tetracycline concentration and cultured for 96 h. For each sample, 1 Â 10 6 cells were washed with PBS and resuspended in 1 ml of propidium iodide staining solution (50 mg/ml propidium iodide, 2.5% formaldehyde, 0.1% NP40, 50 mg/ml RNAse A in PBS) and incubated 15 min. Cells were analyzed for their DNA content and cell cycle phase distribution by flow cytometry (Becton Dickinson) of propidium iodide-stained nuclei. The percentage of cells within each cell cycle compartment was determined by analysis with the CellQuest program (Becton Dickinson). For analysis of cellular differentiation, the immunophenotyping was done as previously described by evaluation of percentage of antigen-positive cells and fluorescence intensity. 21 At 96 h of culturing in the presence of the indicated tetracycline concentration, cells were harvested and stained with FITC-conjugated mouse a-human CD14 (Becton Dickinson) and phycoerythrin (PE)-conjugated mouse a-human CD11b (Immunoquality) mAbs and analyzed by flow cytometry.
Results
High levels of MLL-AF4 expression result in U937T cell growth inhibition
Several independent U937T promonocytic leukemia clones with tetracycline-regulated MLL-AF4 expression in more than
Modulating effects on cell cycle and differentiation of MLL-AF4 C Caslini et al 95% of the cells were identified by indirect immunofluorescence analysis. In selected clones, named A5, B10, and D7, conditional expression of MLL-AF4 was demonstrated by Western analysis using the a-MLL pAb M382 previously described. 13 The cells express the correct size MLL-AF4 fusion protein (240 kDa) when tetracycline is withdrawn from the culture medium while MLL-AF4 is undetectable in cells cultured in the presence of 1 mg/ml tetracycline, or in U937T parental cells grown without tetracycline (Figure 1a) .
Next, we analyzed the effects of MLL-AF4 overexpression on proliferation rate. A5, B10, and D7 clones or U937T parental cells were grown in the absence or presence of tetracycline (1 mg/ml). Clones expressing MLL-AF4 underwent growth inhibition over a period of 72-96 h with a doubling time of 50.573.3 h (Figure 1b) . When tetracycline was used to suppress the expression of MLL-AF4 the cells grew normally and doubled every 25.072.5 h.
Growth of the U937T parental cells was not affected in the absence or presence of tetracycline, with a doubling time of 25.5 and 25.0 h, respectively (average of two experiments).
Throughout 5 days of culture both the U937T parental and selected clones maintained greater than 90% viability, as observed by trypan blue exclusion.
Modulation of cell cycle and differentiation by graded expression of MLL-AF4
To determine whether variable levels of MLL-AF4 could result in a modulation of the growth rate effects observed following overexpression of the oncoprotein, we took advantage of the tetracycline-regulatable system as a reliable experimental model for controlling the amount of MLL-AF4 ectopic expression in a manner inversely proportional to the concentration of repressor in the culture media. [29] [30] [31] Flow cytometric analysis of the representative clone D7 grown 96 h at varying tetracycline concentration confirmed a modulating effect of the MLL-AF4 expression levels on cell cycle progression. Cells cultured without tetracycline and therefore expressing MLL-AF4 at maximal level had one-half of the S phase redistributed in the G1 phase of the cell cycle then compared to nonexpressing cells grown at 1 mg/ml tetracycline (Figure 2 ). At tetracycline concentration ranging from 0.5 to 3 ng/ml, decreasing levels of MLL-AF4 expression resulted in gradual increase of cells in S phase and compensatory decrease of cells in G1 phase, indicating that MLL-AF4 modulation of growth rate occurs at the G1 to S phase transition.
In order to compare the modulation of cell growth and cell cycle induced by MLL-AF4 with other MLL fusion products, we made use of previously described U937T cell lines conditionally expressing MLL-AF9 or MLL3AT proteins. 21 MLL-AF9 overexpression for 96 h resulted in substantial increase of sub-G1 fraction (up to 31%) without significant change in cell cycle distribution when compared to nonexpressing cells grown at 1 mg/ml tetracycline, which confirms that low growth rates of MLL-AF9-overexpressing cells are likely to be due to apoptosis (Figure 2 and Caslini et al 21 ) . By contrast, no substantial appearance of sub-G1 fraction was detected in U937T cells following conditional overexpression of MLL3AT as well as MLL-AF4 (Figure 2) . Instead, up to 90% of the cells were arrested in G1 phase of the cell cycle when cultured for 96 h in the absence of tetracycline. Again, the strength of this phenotype is inversely proportional to the concentration of tetracycline in the medium.
As previously reported, 21 MLL-AF9 is a potent inducer of monocyte/macrophage-specific markers CD11b and CD14 while MLL3AT induces only CD11b expression when conditionally overexpressed in U937T leukemic cells (Figure 3 ). In the A5, B10 and D7 clones analyzed, immunophenotyping showed lack of CD14 expression after 96 h of MLL-AF4 overexpression (data not shown). In the absence of tetracycline, at maximal MLL-AF4 expression, we found that 94% of D7 cells were Growth inhibition by conditional expression of MLL-AF4 in U937T cell line. (a) Western analysis of U937T clones conditionally expressing MLL-AF4. Total cell lysates prepared from the parental cell line (U937T) and three independent clones (A5, B10, and D7) grown 48 h in the presence or absence of 1 mg/ml tetracycline were separated by 5% SDS-PAGE and transferred to nitrocellulose membranes. The MLL-AF4 protein (n) was detected by affinity purified a-MLL pAb M382. (b) Growth curve analysis of A5, B10, and D7 clones. U937T clones were cultured in triplicate at 5 Â 10 4 cells/ml into six-well plates in the absence (ÀTET) or presence ( þ TET) of 1 mg/ml tetracycline and counted every 24 h. Results are presented as mean of triplicate experiments; the s.d. was within 10% of the mean.
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C Caslini et al positive for CD11b while at tetracycline concentration ranging from 0.5 to 3 ng/ml the percentages of CD11b-positive D7 cells were decreased proportionally with their reduced expression of MLL-AF4 ( Figure 3 ). As expected, no expression of CD11b was detected at tetracycline concentration fully repressing MLL-AF4 (1 mg/ml). Thus, graded expression of MLL-AF4 oncoprotein results in partial monocytic differentiation of U937T cells, as demonstrated by induction of CD11b only. Finally, we investigated whether the modulation of cell cycle by high levels of MLL-AF4 ectopic expression may result in a lower sensitivity to cell death stimuli including chemotherapeutic agents. Due to the intrinsic resistance of U93T cells to serum deprivation and their differentiation following interferong treatment, we could not test the effects of MLL-AF4 conditional expression on these stimuli. To assess whether the conditional expression of MLL-AF4 confers resistance to drug-mediated cytotoxicity, D7 and parental U937T cells grown 48 h in the absence or presence of various tetracycline concentrations were exposed 48 h to increasing dose of etoposide (VP-16), a topoisomerase II inhibitor. Cell viability was then analyzed by MTT assay and expressed as percentage of drug-treated vs untreated viable cells. Figure 4 shows the results of a representative experiment. We observed up to a four-fold increase of survival in D7 cells overexpressing MLL-AF4 when exposed to increasing doses of VP-16. This latter effect was not observed in parental U937T cells grown in the absence of tetracycline. Similar findings were found in three independent experiments.
Along the same line, we investigated the expression levels of two antiapoptotic molecules like Bcl 2 and BclX L by Western analysis of D7 cells grown for 96 h at varying concentration of tetracycline. At increasing levels of MLL-AF4 expression D7 cells showed a decrease of Bcl 2 and, in less extent, of BclX L expression levels ( Figure 5 ). Therefore the levels of these antiapoptotic molecules do not contribute on MLL-AF4-induced resistance to VP-16.
In spite of differences in biological activities, U937T clones carrying the MLL-AF4 and MLL-AF9 translocations both in the absence and in the presence of different tetracycline concentrations, expressed comparable levels of the fusion mRNAs when tested by RQ-PCR (data not shown).
Discussion
By using a tetracycline repressor-based conditional expression system, we have demonstrated a regulative role exerted by MLL-AF4 fusion oncoprotein on cell cycle progression and differentiation of U937 myelomonocytic leukemia cells. When induced to overexpress MLL-AF4 by tetracycline withdrawal, the U937 cells undergo growth inhibition with reduction of cells in S phase and redistribution in the G1 phase of the cell cycle. Effects of graded expression of MLL-AF4, MLL-AF9, and MLL3AT on cell cycle distribution. Representative U937T clones conditionally expressing MLL-AF4 (D7), MLL-AF9 (B37), or the MLL3AT (X4) deletion mutant were plated at cell density of 5 Â 10 4 cell/ml and cultured at the indicated concentration of tetracycline. After 96 h, cell cycle distribution was determined by FACS analysis.
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These effects on the cell cycle are accompanied by partial differentiation toward monocytic/macrophage lineage, as shown by induction of CD11b expression. Both the strength of G1 delay and the CD11b expression levels change gradually as the level of MLL-AF4 expression is increased. By comparison, while the MLL3AT carrying the three AT hooks induced a very similar phenotype, the U937T cell lines carrying the MLL-AF9 translocation specifically showed increased sub-G1 peak and a more pronounced monocyte-macrophage differentiation (CD14 expression).
The t(4;11)(q21;q23), creating the MLL-AF4 chimeric transcript, is the predominant 11q23 chromosome translocation occurring in infant ALL. Pro-B ALLs carrying t(4;11) are characterized by high white blood count, accumulation of blasts in extramedullary tissues and poor response to conventional chemotherapy. 32, 33 These clinical traits suggest an alteration in the response of leukemic blast expressing MLL-AF4 fusion protein to programmed cell death-inducing stimuli, which may account for treatment failure. Indeed, t(4;11) positive pro-B ALL cell lines show resistance to serum deprivation-induced or interferon g-regulated, CD95-induced apoptosis, and the presence of abundant levels of Bcl 2 and BclX L were sought to contribute on the resistance to different apoptotic stimuli. 34, 35 In addition, ALL cell lines carrying t(4;11) exhibit increased doubling time with reduced number of cells in cycle when compared to non-t(4;11) B lineage ALL cell cultures. 34 However, it was not clear whether these effects are directly caused by expression of the MLL-AF4 fusion product of t(4;11) or by other genetic alterations present in these cells.
Here, we show that in U937T cells conditionally expressing MLL-AF4 the expression levels of Bcl 2 and BclX L are lower than in parental cells, arguing against a protection to different apoptotic stimuli conferred by direct MLL-AF4 upregulation of these antiapoptotic proteins.
Our findings of a dosage effect of MLL-AF4 conditional expression on growth rate and cell cycle distribution agrees with previous observations of reduced proliferative capacity in t(4;11) positive pro-B ALL cell lines. In addition, gene expression analysis of MLL-rearranged ALLs, both T-and B-lineage, showed downregulation of multiple cell proliferation genes relative to non-MLL ALLs, suggesting that a lower proliferation rate could be a common feature of ALLs expressing different MLL fusion proteins. 36 
Figure 3
Modulation of CD11b levels by graded expression of MLL-AF4. U937T clones conditionally expressing MLL-AF4 (D7), MLL3AT (X4) or MLL-AF9 (B37) were cultured for 96 h in the presence of the indicated concentrations of tetracycline. The cells were stained simultaneously with fluorescein (FITC)-conjugated mouse a-CD14 mAb and phycoerythrin (PE)-conjugated mouse a-CD11b mAb and analyzed by FACS. The histograms represent the PE or FITC fluorescence profiles at different concentration of inhibitor tetracycline. Isotype-control antibodies were used to set up the background level.
Modulating effects on cell cycle and differentiation of MLL-AF4 C Caslini et al Several independent observations have indicated G0/G1 cellcycle accumulation in leukemic cells as a possible further mechanism of resistance to cell-death promoting stimuli. 37, 38 Quiescent cells or those with disrupted cell-cycle checkpoints may display decreased apoptosis following exposure to chemotherapeutic agents and quiescence of myeloid cells can be induced by differentiation. Indeed, in HL60 or U937 cell lines, resistance to drug-induced apoptosis increases with greater duration following incubation with retinoic acid or vitamin D3. 39, 40 This protective effect correlates with the degree of G0/ G1 accumulation but is independent of differentiation status or Bcl 2 expression levels.
The observed increased survival of D7 cells overexpressing MLL-AF4 when exposed to highly cytotoxic levels of VP-16, is in line with previous studies indicating a dependence of topoisomerase II-mediated drug action on proliferative status of the cells. 41, 42 We are tempting to speculate that in t(4;11)-positive blast cells, one of the advantages conferred by higher grade of MLL-AF4 fusion gene expression may be the modulation of cell cycle leading to fewer cells in S phase, accumulation in G1 and prolonged doubling time, which would explain the refractory behavior of a fraction of cells to increasing levels of the topoisomerase II inhibitor VP-16.
We have reported that growth inhibition of U937 cells expressing MLL-AF9 is due to an increase in apoptosis, and is accompanied by induction of monocyte-macrophage-specific markers CD11b and CD14. 21 Interestingly, expression of CD11b and CD14 differentiation markers does not correlate with cell cycle arrest of MLL-AF9 conditionally expressing cells. At every tetracycline concentrations tested, allowing variable levels of MLL-AF9 expression, or at earlier expression time points, 21 we do see proportionally equal or increased percentage of cells in S phase compared to cells without MLL-AF9 expression, arguing for a proliferative advantage conferred by the fusion protein. Accordingly, knockin mice with germline transmission of an Mll-AF9 allele showed selective expansion of CD11b/Gr1-positive myeloid cells as early as 6 days after birth, suggesting a proliferative advantage and a monocytic phenotype maintenance conferred by the Mll-AF9 oncoprotein. 43 Using the U937T cell line as experimental model, we determined different effects contributed by the MLL-AF4 and MLL-AF9 fusion gene products on cell cycle modulation. In particular, our results demonstrate a dosage-dependent effect of MLL-AF4 fusion oncoprotein on cell cycle progression, with increasing levels of expression resulting in the accumulation in G1, prolonged doubling time, both findings that might be responsible for the observed increased resistance to VP-16-mediated cytotoxicity. We propose the cell cycle control exerted by MLL-AF4 may be responsible of resistance to celldeath promoting stimuli and therefore participate on the highly malignant phenotype observed in leukemia carrying the t(4;11) translocation. VP-16-mediated cytotoxicity on U937T cells highly expressing MLL-AF4. U937T parental or D7 clone were grown 48 h in the absence of tetracycline or in the presence of tetracycline concentrations ranging from 0.5 to 1000 ng/ml. The cells were then plated in triplicate at 5 Â 10 4 cells/ml, in the presence of the indicated concentration of VP-16 (2.5-25 mM). Cell viability was determined 48 h later, by using an MTT assay, and calculated as percentage of drug treated vs untreated viable cells. A representative experiment is shown.
Figure 5
Tetracycline concentration-dependent Western blot analysis of Bcl 2 and BclX L . U937T parental or D7 clone conditionally expressing MLL-AF4 were cultured 96 h at the indicated concentration of tetracycline and then cells were lysated in NP-40 buffer. Equal amount of cell lysates were run on 15% SDS-PAGE and electrophoretically transferred to nitrocellulose membrane. The membrane was probed with a-Bcl2 mAb, a-BclX L pAb, and a-Actin pAb as loading control.
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